

AMENDMENTS

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 - 40. (cancelled)

Claim 41 (currently amended): The method according to claim [[96]]71, wherein said carrier liquid consists essentially of a hydrophilic solution of gelatin dissolved in a mixture of water and ethanol, wherein a sweetener is incorporated into said fibers.

Claim 42 (Previously presented): The method according to claim 41, wherein the sweetener is saccharine.

Claims 43 – 70 (Cancelled)

Claim 71 (Previously Presented): A method of manufacturing a rapid dissolving tablet suitable for buccal delivery of an active agent containing one or more active medicaments, comprising the steps of

- (1) supplying a biologically acceptable carrier liquid through a first supply tube to an outlet of said first supply tube, said biologically acceptable carrier liquid comprising a solution of a biologically acceptable polymer;
 - (a) wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, vinylpyrrolidone/vinylacetate copolymer, vinylpyrrolidone/vinylimidazole copolymer, and polyvinyl alcohol in a mixture of water and ethanol[[],]; and
 - (b) wherein said water and ethanol are present in said carrier liquid at a ratio of from about 1:0.8 to about 1:1.5, through a first supply tube to an outlet of said first supply tube;

- (2) establishing an electric field between the outlet of said first supply tube and a support surface that is spaced from the outlet to cause liquid issuing from the outlet to form at least one fiber or fibrils of said carrier liquid;
- (3) causing said fibers or fibrils to deposit onto the support surface to form a fibrous porous web or mat;
- (4) supplying a biologically acceptable carrier liquid comprising an active medicament through a second supply tube to an outlet of said second supply tube;
- (5) applying a charge to said carrier liquid of Step 4 opposite the charge of said first electric field of Step 2 to form a layer of fibers or fibrils comprising said active ingredient on top of said fibrous porous web or mat ~~the layer of fibers from Step 3~~;
- (6) repeating Steps 1- 3 so as to deposit a layer of fibers or fibrils on the surface of the layer of fibers or fibrils of active ingredient from Step 5; and
- (7) forming a plurality of individual tablets from the layers produced from step 6, of sandwich of fiber web or mat, fibers of active ingredient and fiber web or mat; and

wherein the individual tablets are capable of rapid dissolution suitable for buccal delivery.

Claim 72 (cancelled):

Claim 73 (currently amended): The method according to claim ~~[[72]]~~ 71 wherein said biologically acceptable polymer is ~~selected from the group consisting of gelatin, polyvinyl pyrrolidone, polyvinyl alcohol having a molecular weight of from about 100,000 to about 130,000, vinylpyrrolidone/vinylacetate copolymer, vinylpyrrolidone/vinylimidazole copolymer, poly-sucrose, starch, cellulose, and sugars.~~

Claim 74 -76 (cancelled)

Claim 77 (currently amended): The method according to claim ~~[[75]]~~ 71 wherein said biologically acceptable polymer is gelatin.

Claim 78 -81 (cancelled)

Claim 82 (Previously presented): The method according to claim 81 wherein said biologically acceptable polymer is polyvinyl pyrrolidone.

Claim 83 -89 (Cancelled)

Claim 90 (currently amended): The method according to claim ~~[[86]]~~ 71 wherein said active ingredient is a confectionary material.

Claim 91 (Previously presented): The method according to claim 71 wherein said active ingredient is a medicament for a human or an animal.

Claim 92 (Previously presented): The method according to claim 91 wherein said active ingredient is a medicament for an animal.

Claim 93 (currently amended): The method according to claim ~~[[90]]~~ 91 wherein said active ingredient is a medicament for a human.

Claim 94 (Previously presented): The method according to claim 91 wherein said active ingredient is a medicament selected from the group consisting of a drug, vaccine, enzyme or diagnostic agent.

Claim 95 - 98 (Cancelled)